Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Neural tube defects (NTDs) are preventable through preconceptional and periconceptional folic acid intake. Although decreases in the prevalence of NTDs have been reported since folic acid fortification of United States grain products began, it is not known whether folic acid plays a role in reducing the severity of occurring NTDs. Our aim was to determine whether survival among infants born with spina bifida and encephalocele has improved since folic acid fortification and to measure the effects of selected maternal, pregnancy, and birth characteristics on first-year (infant) survival rates.
Methods: A retrospective cohort study was conducted and included 2841 infants with spina bifida and 638 infants with encephalocele who were born between 1995 and 2001 and were registered in any of 16 participating birth defects monitoring programs in the United States. First-year survival rates for both spina bifida and encephalocele cohorts were measured with Kaplan-Meier estimation; factors associated with improved chances of first-year survival, including birth before or during folic acid fortification, were measured with Cox proportional-hazards regression analysis.
Results: Infants with spina bifida experienced a significantly improved first-year survival rate of 92.1% (adjusted hazard ratio: 0.68; 95% confidence interval: 0.50-0.91) during the period of mandatory folic acid fortification, compared with a 90.3% survival rate for those born before fortification. Infants with encephalocele had a statistically nonsignificant increase in survival rates, ie, 79.1% (adjusted hazard ratio: 0.76; 95% confidence interval: 0.51-1.13) with folic acid fortification, compared with 75.7% for earlier births.
Conclusions: Folic acid may play a role in reducing the severity of NTDs in addition to preventing the occurrence of NTDs. This phenomenon contributes to our understanding of the efficacy of folic acid. Additionally, as survival of NTD-affected infants improves, health care, education, and family support must expand to meet their needs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/peds.2005-1364 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
JAMA
September 2025
Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands.
Importance: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks.
Objective: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth.
Antibacterial and anticancer activity of multifunctional iron-based magnetic nanoparticles against urinary tract infection and cystitis-related bacterial strains and bladder cancer cells.
Biomed Eng Lett
September 2025
Department of Electrical & Biological Physics, Kwangwoon University, Seoul, 01897 Republic of Korea.
Purpose: This study investigates the antibacterial and anticancer activity of previously reported iron oxide (FeO)-based nanoparticles (NPs) conjugated with chlorin e6 and folic acid (FCF) in photodynamic therapy (PDT) using a human bladder cancer (BC) (T-24) cell line and three bacterial strains.
Method: To investigate the potential applicability of the synthesized NPs as therapeutic agents for image-based photodynamic BC therapy, their photodynamic anticancer activity was analyzed and the mechanisms of cell death in T-24 cells treated with these NPs were assessed qualitatively and quantitatively through atomic absorption spectroscopy, fluorescence imaging, and transmission electron microscopy.
Results: The effective localization of FCF NPs in T-24 cells were confirmed, validating their excellent cellular fluorescence and magnetic resonance imaging capabilities.
Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018-2022.
Cancer Med
September 2025
Adem Crosby Cancer Centre, Department of Medical Oncology, Division of Cancer Care Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
Background: The three main chemotherapy regimens for people with unresectable pancreatic cancer include modified FOLFIRINOX (comprising oxaliplatin, irinotecan and fluorouracil, denoted mFFX), gemcitabine with nab-paclitaxel (GnP), and single-agent gemcitabine (GEM). We explored characteristics associated with the type of chemotherapy and variations in survival.
Materials And Methods: Records for people with unresected pancreatic adenocarcinoma between 2018 and 2022 treated with first-line mFFX, GnP or GEM were extracted from the population-based Queensland Oncology Repository.
Folic acid conjugated magnetic chitosan nanocomposite for the targeted delivery of dual anticancer drugs to breast cancer and hyperthermia therapy.
Int J Biol Macromol
September 2025
Crystal Growth Centre, Anna University, Chennai, 600025, Tamil Nadu, India.
Increase in breast cancer has led to the search for systems that can enable, targeted, sustained and prolonged release of drugs while simultaneously reducing the side effects posed by them. In light of this, folic acid-conjugated 5-Fluorouracil and doxorubicin loaded chitosan/Fe₃O₄ (FA-dual@CS/Fe₃O₄) nanocomposite has been synthesized using the chemical method for targeted breast cancer therapy in addition to CS/FeO and dual drug encapsulated CS/FeO. FTIR and XPS studies confirm the successful drug encapsulation and FA conjugation.
View Article and Find Full Text PDFA novel treatment for diabetic nephropathy: Folate receptor-targeted delivery of TLR4 siRNA via functionalized PLGA nanoparticles in streptozotocin-induced diabetic murine models.
Nanomedicine
September 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S
Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.
View Article and Find Full Text PDF